Chimeric Therapeutics Limited (ASX:CHM)
Australia flag Australia · Delayed Price · Currency is AUD
0.0020
0.00 (0.00%)
At close: Mar 27, 2026

Chimeric Therapeutics Revenue

Chimeric Therapeutics had revenue of 2.62M AUD in the half year ending December 31, 2025, a decrease of -76.12%. This brings the company's revenue in the last twelve months to 9.75M, up 377.63% year-over-year. In the fiscal year ending June 30, 2025, Chimeric Therapeutics had annual revenue of 12.68M with 70.09% growth.

Revenue (ttm)
9.75M
Revenue Growth
+377.63%
P/S Ratio
0.91
Revenue / Employee
n/a
Employees
n/a
Market Cap
8.84M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Jun 30, 202512.68M5.23M70.09%
Jun 30, 20247.46M2.95M65.52%
Jun 30, 20234.51M1.89M72.16%
Jun 30, 20222.62M--
Jun 30, 2021---
Jun 30, 2020 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
Immuron7.48M
Tissue Repair3.38M
Acrux2.81M
Nexalis Therapeutics761.96K
AdAlta608.07K
Bio-Gene Technology390.63K
Invex Therapeutics229.08K
Patrys100.38K
Revenue Rankings